CareDx, Inc (CDNA)
After hours:
| Previous Close | 13.18 |
| Open | 13.09 |
| Bid | 13.05 x 2200 |
| Ask | 14.05 x 800 |
| Day's Range | 12.91 - 13.43 |
| 52 Week Range | 11.92 - 47.82 |
| Volume | |
| Avg. Volume | 939,476 |
| Market Cap | 707.763M |
| Beta (5Y Monthly) | 1.02 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.95 |
| Earnings Date | Feb 22, 2023 - Feb 27, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 30.00 |
- Business Wire
Independent Prospective Study Defines Reference Range for CareDx’s AlloSure for Long-Term Lung Transplant Surveillance
BRISBANE, Calif., December 01, 2022--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced the results of a new study published in Transplantation Direct1 which establishes a reference baseline when using AlloSure® Lung in the long-term surveillance of lung transplant patients.
- Zacks
Here's Why CareDx (CDNA) Could be Great Choice for a Bottom Fisher
CareDx (CDNA) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
- Zacks
CareDx (CDNA) Loses 22.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
CareDx (CDNA) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
